Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Bradley Rivotto
A Phase 1/2 Study of Evofosfamide, a Hypoxia-Activated Prodrug With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma
Case Reports in Hematology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma
Investigational New Drugs
Oncology
Pharmacology
Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study
British Journal of Cancer
Cancer Research
Oncology
A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
